September 20, 2022 — Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the 

September 19, 2022 —  Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., H

September 19, 2022 — Puzzle Medical Devices, a provider of hemodynamic support in Heart Failure (HF), was selected as the winner of the TCT 2022 Innovation Shark Tank Competition.

September 19, 2022 —  A first-in-human (FIH) study using the ModulHeart device (Puzzle Medical Devices Inc.) has demonstrated significant improvement in cardiac output, left ventricular end diastolic pressure, and urine output in patients with

September 19, 2022 —  HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead electrocardiogram (ECG) patch monitor intended for detection of acute coronary syndr

Technology-enabled “Insourcing” approach to cardiac arrhythmia diagnosis provides patient and provider benefits

September 17, 2022 — Abbott today announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating people with a range of structural heart diseases.

September 17, 2022 — Medtronic today announced findings from its Pathological Study of Hypo-Attenuated Leaflet Thickening (HALT) in Self-Expanding Transcatheter Aortic Valves, as part of the CoreValve Evolut Program. The study is the first to compare microCT and histology findings of valve leaflet thickening, the results of which may provide clinical insights for long-term durability of transcatheter aortic valves (TAVs) and treatment of HALT.

Subscribe Now